PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
17.97%
Revenue growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 3.06%. Joel Greenblatt would investigate if growth quality matches quantity.
25.11%
Cost growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 4.80%. Jim Chanos would check for structural cost disadvantages.
-9.53%
Gross profit decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive position.
-23.31%
Margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive position.
188.72%
R&D change of 188.72% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
-32.89%
G&A reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate efficiency gains.
48.76%
Marketing expense change of 48.76% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
156.00%
Other expenses change of 156.00% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify efficiency.
-8.86%
Operating expenses reduction while Drug Manufacturers - Specialty & Generic median is 5.25%. Seth Klarman would investigate advantages.
10.87%
Total costs growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 6.89%. Jim Chanos would check for waste.
41.73%
Interest expense change of 41.73% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify control.
48.75%
D&A growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.53%. Jim Chanos would check for overinvestment.
94.19%
EBITDA growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
131.61%
Margin change of 131.61% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
-37.46%
Operating income decline while Drug Manufacturers - Specialty & Generic median is -7.15%. Seth Klarman would investigate causes.
-16.53%
Operating margin decline while Drug Manufacturers - Specialty & Generic median is -8.34%. Seth Klarman would investigate causes.
152.56%
Other expenses change of 152.56% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify control.
113.77%
Pre-tax income growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
111.67%
Pre-tax margin growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
-1.72%
Tax expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
111.86%
Net income growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
110.06%
Net margin growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
116.82%
EPS growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
116.82%
Diluted EPS growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
68.21%
Share count change of 68.21% versus stable Drug Manufacturers - Specialty & Generic. Walter Schloss would verify approach.
68.21%
Diluted share change of 68.21% versus stable Drug Manufacturers - Specialty & Generic. Walter Schloss would verify approach.